Amgen

Buckle up AbbVie, Amgen: Biohaven's oral CGRP drug is gaining traction in migraine, doctors’ survey shows
Fierce Pharma
Fri, 10/22/21 - 12:42 pm
Biohaven
migraines
Nurtec ODT
Amgen
AbbVie
Amid Amgen's similar struggles, AstraZeneca slams the brakes on MCL-1 blood cancer drug
Fierce Biotech
Wed, 10/20/21 - 10:20 am
AstraZeneca
AZD5991
clinical trials
Amgen
blood cancer
Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs
MedCity News
Thu, 10/7/21 - 12:19 pm
Neumora Therapeutics
R&D
Amgen
funding
data science
drug development
Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster
Fierce Biotech
Thu, 10/7/21 - 11:24 am
Bristol Myers Squibb
deucravacitinib
Amgen
Otzela
psoriasis
ulcerative colitis
Biopharma needs a biggie to avoid a down deal year
EP Vantage
Thu, 10/7/21 - 11:07 am
M&A
Merck
Acceleron
Sanofi
Translate Bio
Amgen
Teneobio
Pfizer
Trillium
Perrigo
HRA Pharma
Amgen reveals midphase eczema data behind its $400M bet
Fierce Biotech
Mon, 10/4/21 - 10:38 am
Amgen
Kyowa Kirin
clinical trials
eczema
antibodies
Amgen receives FDA approval for Repatha to treat pediatric HeFH patients
Pharmaceutical Business Review
Mon, 09/27/21 - 11:00 am
Amgen
Repatha
FDA
pediatric
HeFH
Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028
Fierce Pharma
Tue, 09/21/21 - 10:54 am
Amgen
Otezla
psoriasis
generics
Sandoz
market exclusivity
patents
ESMO: Mirati pulls away from Amgen in colorectal cancer with rival KRAS drug
Fierce Biotech
Mon, 09/20/21 - 12:00 am
ESMO
Mirati Therapeutics
Amgen
colorectal cancer
Amgen to advance KRAS drug combination after improved results in colon cancer
BioPharma
Thu, 09/16/21 - 10:40 pm
Amgen
Lumakras
clinical trials
colon cancer
ESMO Preview: Highlights to Watch for This Year
BioSpace
Wed, 09/15/21 - 10:29 pm
ESMO
oncology
cancer
Gilead Sciences
Bristol Myers Squibb
Zymeworks
Amgen
Adaptimmune Therapeutics
TCR2 Therapeutics
Boehringer Ingelheim
ESMO 2021 – Mirati bids to be belle of the ball
EP Vantage
Tue, 09/14/21 - 10:41 am
ESMO
Mirati Therapeutics
Faron Pharmaceuticals
Amgen
Spectrum Pharmaceuticals
Amgen's high-profile cancer med Lumakras set for rollout in England thanks to NHS access deal
Fierce Pharma
Sat, 09/11/21 - 10:18 pm
Amgen
Lumakras
UK
NHS
cancer
Cardiff reveals early data on challenger to Amgen's KRAS crown
Fierce Biotech
Thu, 09/9/21 - 11:20 pm
Cardifff Oncology
Amgen
Onvansertib
colorectal cancer
No joy for Ajovy: Teva's migraine drug can't find a win in meta-analysis versus Biohaven, AbbVie meds
Fierce Pharma
Thu, 09/9/21 - 11:11 am
Teva Pharmaceutical
Eli Lilly
Amgen
Ajovy
Biohaven
migraines
Amgen builds case for severe asthma drug tezepelumab
Pharmaforum
Mon, 09/6/21 - 09:11 pm
Amgen
AstraZeneca
tezepelumab
asthma
nasal polyps
Merck, Amgen adopt double-digit price hikes in test to Big Pharma's unofficial annual limits: analyst
Fierce Pharma
Wed, 09/1/21 - 11:23 am
Merck
Amgen
drug pricing
J&J, Amgen and Roche face growing biosimilar competition that is driving down prices: report
Fierce Pharma
Thu, 08/12/21 - 11:04 pm
JNJ
Amgen
Roche
biosimilars
drug pricing
Mirati fiddles as its share price burns
EP Vantage
Thu, 08/12/21 - 11:07 am
Mirati Therapeutics
Amgen
Lumakras
adagrasib
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
BioPharma Dive
Tue, 08/10/21 - 11:12 pm
M&A
Bayer
Sanofi
Amgen
uniQure
MorphoSys
Xeris Pharmaceuticals
Relay Therapeutics
Merck
Beam Therapeutics
Jazz Pharmaceuticals

Pages